MINNEAPOLIS, Feb 21, 2018 Invenshure portfolio company, OneOme, a healthcare technology company whose genetic test helps predict how a person will respond to hundreds of medications, announced it was named to Fast Company's World's 50 Most Innovative Companies list, as well as the Top 10 Most Innovative Companies in Biotech for 2018 in the publication's annual issue. OneOme numbered second in the Top 10 in biotech category and 22nd of 50 in the overall list.
In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering personalized medicine and care in medical oncology, gastroenterology, and family medicine.
Today, OneOme announced it has been named a finalist for the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards in the Healthcare category. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership. OneOme’s RightMed® pharmacogenomic solution identifies how a patient’s DNA and current medications may affect their response to medications.
Next week, OneOme will participate in the Individualizing Medicine 2017 Conference in Rochester, Minn. The event, which is hosted by the Mayo Clinic Center for Individualized Medicine, features experts from around the world sharing advice on the practical application of genomic and precision medicine.
OneOme today launched several significant upgrades to its RightMed® pharmacogenomics solution. The RightMed solution now includes an additional gene (SLC6A4), a streamlined psychiatry report, a secure tool for patients to share their results with other providers, and insurance billing. The upgrades expand the utility of OneOme’s RightMed comprehensive test and supporting products.